Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection
- PMID: 23435301
- PMCID: PMC4063793
- DOI: 10.1097/QAD.0b013e3283601144
Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection
Abstract
Objective: Some antiretroviral treated HIV-infected patients develop Kaposi's sarcoma despite long-term suppression of HIV replication. These Kaposi's sarcoma lesions are consistent with Kaposi's sarcoma observed in the elderly uninfected population ('classical Kaposi's sarcoma'). We investigated potential mechanisms for this phenomenon, focusing on measures of immune activation and T-cell senescence.
Design: We compared markers of immunosenescence, naive T cells, activation, and inflammation in CD4+ and CD8+ T cells from antiretroviral-treated participants with new-onset Kaposi's sarcoma (cases, n = 19) and from treated individuals without Kaposi's sarcoma (controls, n = 47).
Results: There was increased frequency of CD4+ and CD8+ T cells with an immunosenescence phenotype (CD57+ and CD28-) in cases vs. controls (CD4+ T cells: CD57+ 7.4 vs. 3.7%, P = 0.025; CD28- 9.1 vs. 4.8%, P = 0.025; CD8+ T cells: CD57+ 41.5 vs. 27.7%, P = 0.003; CD28- 60.5 vs. 51.3%, P = 0.041). Cases had lower proportions of naïve T cells (CD27+ CD28+ CD45RA+) in CD4+ (23.0 vs. 32.2%, P = 0.023) and CD8+ (11.3 vs. 20.7%, P < 0.001) T-cell compartments. CCR5 was more highly expressed in CD4+ (16.3 vs. 11.0%, P = 0.025), and CD8+ (43.1 vs. 28.3%, P < 0.001) T-cell compartments in cases vs. controls. There was no difference in telomere length or telomerase activity in peripheral blood mononuclear cells, or in T-cell expression of activation markers (HLADRCD38).
Conclusion: Among antiretroviral-treated patients, increased frequencies of T cells with an immunosenescence phenotype and lower frequencies of naive T cells were associated with presence of Kaposi's sarcoma among effectively treated patients. These data suggest that certain immunologic perturbations--including those associated with aging--might be causally associated with development of Kaposi's sarcoma.
References
-
- Abbaszadeh S, Taheri S. Kaposi's sarcoma after renal transplantation. Saudi J Kidney Dis Transpl. 2009;20:775–778. - PubMed
-
- Aronovitch SA. Dermatological management of Kaposi sarcoma. Dermatol Nurs. 1995;7:191–195. - PubMed
-
- Eltom MA, Jemal A, Mbulaiteye SM, Devesa SS, Biggar RJ. Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst. 2002;94:1204–1210. - PubMed
-
- Gallafent JH, Buskin SE, De Turk PB, Aboulafia DM. Profile of patients with Kaposi's sarcoma in the era of highly active antiretroviral therapy. J Clin Oncol. 2005;23:1253–1260. - PubMed
-
- Serraino D, De Paoli A, Zucchetto A, Pennazza S, Bruzzone S, Spina M, et al. The impact of Kaposi sarcoma and non-Hodgkin lymphoma on mortality of people with AIDS in the highly active antiretroviral therapies era. Cancer Epidemiol. 2010;34:257–261. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- P30 MH062246/MH/NIMH NIH HHS/United States
- AI 28697/AI/NIAID NIH HHS/United States
- K24AI069994/AI/NIAID NIH HHS/United States
- K24 AI069994/AI/NIAID NIH HHS/United States
- P30AI027763/AI/NIAID NIH HHS/United States
- UL1 RR024131/RR/NCRR NIH HHS/United States
- P30 AI045008/AI/NIAID NIH HHS/United States
- R24 AI067039/AI/NIAID NIH HHS/United States
- P30 AI028697/AI/NIAID NIH HHS/United States
- R01 AI087145/AI/NIAID NIH HHS/United States
- UL1RR024131/RR/NCRR NIH HHS/United States
- P30 AI027763/AI/NIAID NIH HHS/United States
- T32 AR007175/AR/NIAMS NIH HHS/United States
- P30 MH62246/MH/NIMH NIH HHS/United States
- P30 AI 045008/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials